Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0006142 (breast cancer)
 160,383 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Combination chemotherapy with cyclophosphamide (CPA), adriamycin (ADR) and 5-fluorouracil (5-FU) (CAF therapy) was performed in 85 patients with advanced and recurrent breast cancer. According to the response criteria for advanced breast cancer by the Japan Mammary Cancer Society, complete response was obtained in 6 cases and partial response in 19 and an overall effective rate was 29.4% (25/85). In terms of efficacy classified by metastatic lesion, the effective rate was more than 40% in skin and subcutaneous tissue, and lymph nodes, but if was low in bone metastases. Alopecia, leukopenia, nausea and vomiting were observed very frequently as side effects, but they disappeared within three weeks, except alopecia. CAF therapy is considered to be useful in the treatment of advanced and recurrent breast cancer.
 ...
PMID:[Combination chemotherapy of cyclophosphamide adriamycin and 5-fluorouracil (CAF) in advanced and recurrent breast cancer]. 718 31

In cases of recurrent progressive breast cancer, ADM, CPM, 5-FU, MTX, MMC and vinca alkaloids have proven to be effective, but CMF and CAF have been considered the standard chemotherapy regimen. But no regimen can cure recurrent progressive breast cancer. Thus, the aim in recent years has been greater efficacy and longer survival by means of dose-intensity. The latter has become possible through G-CSF, the patient's own bone marrow transplant or implantation of peripheral vascular cells and the like, resulting in 70-90% efficacy. The CR rate also has reached over 50%, and long-term survival has been achieved. Clinical research has been thus moving ahead, encouraged by the promise of chemotherapy employing such huge doses. However, in combination with other forms of therapy, a great number of controversial problems are encountered which require study. Recently, a number of agents such as Taxotere or CPT-11 have been used effectively in combination for breast cancer, and they appear to be very promising.
 ...
PMID:[Recent advance in chemotherapy for breast cancer]. 772 95

Chemotherapy plays a major indispensable role in treating patients with recurrent breast cancer. Although standard regimens such as CAF, FAC or CMF yield approximately a 50% response rate, the response usually lasts only for 6 months or so on average. For those who have an unfavorable response to chemotherapy, significant portions of their remaining time are to be consequently lost with only identifying damaging effects of treatment, depressed quality of life. Because of this dismal outcome, many of the patients are deeply discouraged about the future, and there is a desperate need for better treatment. Autologous stem cell support, originally practiced in the form of autologous bone marrow transplantation, has been found instrumental in treating breast cancer, and our pilot study started some fifteen years ago showed a higher response rate and survival rate compared to conventional chemotherapy. Moreover, there have been some long-term disease-free survivors with probable cures among complete responders. This is because quality of life is not a mere rating of health status, and is something perceived by each patient individually, reflecting the way in which individual patients feel about their health status. Although high-dose chemotherapy with autologous stem cell support will cause quite a lower quality of life for a significant period of time, it has been fairly well accepted and tolerated by many patients who would be able to maintain some degree of hope. The need to incorporate patients' values, preferences and hopes is what distinguishes quality of life from all other health measures, and physicians' values ought to play no major role in the decision making process when the outcome is often palliation and treatments may be unpleasant.
 ...
PMID:[Chemotherapy for patients with recurrent breast cancer and quality of life]. 774 86

The aim of a retrospective study was to evaluate efficacy of three modalities of adjuvant therapy for patients who had breast cancer with more than ten positive axillary nodes. One hundred eighteen patients underwent extended radical mastectomy and 48 patients underwent radical mastectomy. Eight six patients received chemotherapy which included CAF or other, 18 patients underwent surgical endocrine therapy, 37 patients had irradiation using 60 cobalt or LINAC, 18 patients had surgery alone or insufficient dose of chemotherapy, Five year survival and 10 years survival for each modalities of adjuvant therapy were as follows: 48% 18% for chemotherapy, 45%, 18% for surgical endocrine therapy, 28%, 12% for irradiation, however a statistical difference was not yet confirmed between chemotherapy and irradiation (chi 2 = 3.00). Four patients were healthy and another four patients were alive with recurrent disease at time of postoperative 10 year. Currently, intensive chemotherapy with ABMT or PBSCT is adopted for those who had a high number of involved axillary nodes. The exact comparison between conventional adjuvant therapy and a new modality will be required.
 ...
PMID:[Adjuvant therapy for breast cancer patient with 10 or more involved nodes]. 774 98

One hundred patients with metastatic breast cancer were randomly selected to receive combined chemotherapy treatment with adriamycin (50 mg/m2) or mitoxantrone (12 mg/m2) associated with 5-fluorouracil (600 mg/m2) and cyclophosphamide (600 mg/m2) administered intravenously every 21 days with a maximum of ten cycles. All patients included in this study were under 75 years of age and had ECOG performance status of less than 4. They had not been treated previously with chemotherapy for metastatic disease. Patients treated with adjuvant chemotherapy, which could not have included anthracyclines, had to have relapsed at least 12 months after the completion of therapy. There were no statistically significant differences in pretreatment characteristics or metastatic disease location between the two groups. Ninety-four patients were assessable for response. No differences were observed in response rate or in survival between the groups. The response rate (complete response (CR) and partial response (PR)) was 68% (13% CR and 55% PR for CAF; 0% CR and 68% PR for CNF). Median survival for all patients was 19 months (18 months with CAF and 19 months with CNF). All patients were assessable for toxicity. There were no differences in gastrointestinal and cardiac toxicity. More grade I-II hematologic toxicity episodes (p < 0.001) and treatment delays (p = 0.05) due to leucopenia were observed with the CNF group, and more grade III alopecia (p < 0.001) was observed with the CAF group. Patients received further therapeutic manoeuvres after finishing the study with a sequential treatment consisting of hormonal therapy and chemotherapy with mitomycin (M) -vinblastine (Vbl) (M 10 mg/m2 day 1, Vbl 5 mg/m2 days 1, 15 and 29; maximum 5 cycles). This chemotherapy treatment was received by 32 patients, with a response rate of 34% and grade III-IV hematologic toxicity of 37%. Treatment with CNF can be considered a good alternative to CAF for first-line treatment of metastatic breast cancer. M-Vbl treatment is useful as second-line treatment in patients with prior adriamycin exposure.
Breast Cancer Res Treat 1995 Apr
PMID:A phase III randomized trial of cyclophosphamide, mitoxantrone, and 5-fluorouracil (CNF) versus cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) in patients with metastatic breast cancer. 774 56

We reported 2 cases of breast cancer with lymph node metastasis treated with CAF (cyclophosphamide, adriamycin, 5-fluorouracil) and medroxyprogesterone acetate (MPA). Case 1 was stage IV [T4b, N3 M1 (lung)] and case 2 was stage IIIa (T1, N2, M0). The two cases responded well to CAF and MPA therapy in local and systemic lesions, and then underwent radiotherapy and lymph node resection without mastectomy. After these treatments, both cases were thought to be disease-free. Major side effects were allopecia, obesity, and leukopenia. These results suggest that combination chemoendotherapy, radiotherapy, and surgery can be utilized for most patients with moderately advanced breast cancer.
 ...
PMID:[Two cases of advanced breast cancer effectively treated with chemoendocrine therapy and radiotherapy]. 794 99

This paper presents a case with lung metastases from breast cancer. Complete response was obtained by combined chemoendocrine therapy with 5'-DFUR and MPA. The patient was a 62-year-old female. She underwent a standard radical mastectomy in April, 1988. The primary legion was ER (-) and PgR (-). Postoperative treatments using CMF and CAF were eventually discontinued owing to profound damage to the bone marrow. An adjuvant chemotherapy with UFT has been employed since. Two years and 7 months later, hemosputum and coughing appeared, and metastases to the lung were revealed. Combined chemoendocrine therapy with 5'-DFUR and MPA was undertaken. A significant decrease in tumor size was observed 3 months after the chemoendocrine therapy was begun, and complete response was obtained at the 8th month. The state has been maintained for one year and 9 months. The use of combined chemoendocrine therapy with 5'-DFUR and MPA in patients for whom intensive chemotherapy is not possible due to damage to bone marrow function is considered effective for its antitumor effects or maintaining patients' quality of life.
 ...
PMID:[A case of complete response of breast cancer with pulmonary metastases to combination therapy of 5'-DFUR and MPA]. 797 28

Patient's perceptions of side effects and the influence of treatment on daily activities are important considerations in choosing a chemotherapy regimen. However, there are no studies comparing patients' experiences with three commonly used chemotherapy regimens for breast cancer. The authors compared the patient-reported side effects and disruption in usual activities for cyclophosphamide and fluorouracil combined with methotrexate (CMF), doxorubicin (CAF), or mitoxantrone (CNF) in 86 women receiving treatment for breast cancer. The incidence and severity of side effects and disruption in usual activities were recorded by patients in a self-care diary (SCD) 2 and 5 days after the first and second drug cycles. Patients reported a mean of 3.2 to 4.9 side effects at each point in time. Fatigue, nausea, anorexia, taste changes, and headache were the most frequently reported side effects and did not differ in incidence among the three drug regimens. When repeated measures analysis of covariance was conducted using mean substitution for missing data and controlling for stage of disease, women receiving CAF reported more severe nausea than women receiving CMF or CNF (P < 0.05). Fatigue was significant for time; however, a distinct clinical pattern of fatigue was not apparent. Patients reported moderate levels of disruption in activities of daily living, with those receiving CAF having greater disruption. There was no difference among treatment groups in reports of overall disruption in activities. These data on patient reported experiences with side effects of chemotherapy can be used to prepare patients for specific side effects of treatment and facilitate symptom management.
 ...
PMID:A comparison of patient-reported side effects among three chemotherapy regimens for breast cancer. 805 7

Clinical, ultrasound and ECG studies of the left ventricle ejection fraction (LVEF) carried out in 25 patients with extensive breast cancer in the course of 148 cycles of standard CAF combination therapy established a protective effect of cardioxane (ICRF-187, dexrazoxane) treatment against the cardiotoxicity of doxorubicin, administered in the maximal cumulative dose of 850 mg/sq. m (decrease in LVEF over 20% as compared with basal level, without clinical symptoms of cardiomyopathy or ECG-revealed disturbances in 0.6% of cycles). 1000 mg/sq.m cardioxane, administered in conjunction with doxorubicin in the ratio of 20:1, neither inhibited the antitumor activity of chemotherapy nor contributed to untoward side-effects which are not associated with cardiotoxicity.
 ...
PMID:[Prevention of cardiotoxicity of doxorubicin (Adriamycin) using cardioxane (ICRF-187, dexrazoxane) in the combination chemotherapy of disseminated breast cancer]. 807 71

We retrospectively evaluated the computed tomography (CT) findings in 20 patients with pulmonary drug toxicity that followed high-dose chemotherapy and autologous bone marrow transplantation (ABMT). Eighty-five patients with Stage II or III breast cancer that involved > or = 10 axillary lymph nodes were enrolled in a treatment protocol that included four cycles of standard-dose therapy (CAF) followed by one cycle of high-dose treatment (CPA/cDDP/BCNU). After chemotherapy, ABMT was performed. Twenty-six patients (31%) developed pulmonary drug toxicity. Serial thoracic CT studies were available in 20 of these 26 patients. All 20 patients exhibited clinical symptoms (i.e., dyspnea, nonproductive cough, and fever) and abnormal pulmonary function following transplantation. Thirteen patients had pathologically proven drug toxicity, and seven patients had clinical features and treatment responses highly suggestive of this diagnosis. Multiple sputum and blood cultures were negative in all patients. CT scans of 13 patients (65%) demonstrated scattered, predominantly peripheral ground-glass or consolidated opacities that occasionally looked nodular or masslike. Two patients (10%) had CT scans suggestive of pulmonary edema and in five patients (25%), the CT examinations revealed no significant abnormalities. Pleural effusions and adenopathy were uncommon. Pulmonary drug toxicity after high-dose chemotherapy and ABMT should be suspected in the appropriate clinical and radiographic setting, and therapy may be initiated on the basis of these observations.
 ...
PMID:Pulmonary drug toxicity following high-dose chemotherapy with autologous bone marrow transplantation: CT findings in 20 cases. 820 80


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>